Pipeline

Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Platform - AssetIndication
Phase 1
Phase 2
Phase 3
Post-Market
Ophtha - NGFFront-of-the-eye: Neurotrophic Keratitis
Ophtha - NGFFront-of-the-eye: Sjogren-related Dry Eye
Ophtha - NGF IntravitrealBack-of-the-eye
NETosis - ReparixinCommunity Acquired Pneumonia (CAP)
NETosis - ReparixinAcute Respiratory Distress Syndrome (ARDS)
NETosis - LadarixinType 1 Diabetes – Early Onset
NETosis - LadarixinType 1 Diabetes – Insulin resistant
Primary Care - KLS-GabaLow-back pain
Ophtha - NGF
Indication: Front-of-the-eye: Neurotrophic Keratitis
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Ophtha - NGF
Indication: Front-of-the-eye: Sjogren-related Dry Eye
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Ophtha - NGF Intravitreal
Indication: Back-of-the-eye
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Reparixin
Indication: Community Acquired Pneumonia (CAP)
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Reparixin
Indication: Acute Respiratory Distress Syndrome (ARDS)
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Ladarixin
Indication: Type 1 Diabetes – Early Onset
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Ladarixin
Indication: Type 1 Diabetes – Insulin resistant
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Primary Care - KLS-Gaba
Indication: Low-back pain
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Latest Publications

Sars-Cov-2
Pain & Antiflammation
Oncology
Ophthalmology
Preclinical Programs

MEDIATE - Molecular Docking at home: Turning collaborative simulations into therapeutic solutions

30/05/2023
Authors: Giulio Vistolia, Candida Manelfib, Carmine Talaricob, Anna Favab, Arieh Warshelc, Igor V. Tetkod,p, Rossen Apostolove, Yang Yef, Chiara Latinig, Federico Ficarellig, Gianluca Palermoh, Davide Gadiolih, Emanuele Vitalih, Gaetano Varrialei, Vincenzo Pisapiai, Marco Scaturroj, Silvano Colettik, Daniele Gregoril, Daniel Gruffatm, Edgardo Leijam, Sam Hessenauerm, Alberto Delbiancon, Marcello Allegrettio, Andrea R. Beccari
Published in:
Taylor & Francis
Sars-CoV-2

Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2

19/05/2023
Authors: Silvia Stella Barbieri, Franca Cattani, Leonardo Sandrini, Magda Maria Grillo, Alessandra Amendola, Carmen Valente, Carmine Talarico, Daniela Iaconis, Gabriele Turacchio, Miriam Lucariello, Lucia Lione, Erika Salvatori, Patrizia Amadio, Gloria Garoffolo, Mariano Maffei, Francesca Galli, Andrea Rosario Beccari, Giuseppe Sberna, Emanuele Marra, Marica Zoppi, Michael Michaelides, Giuseppe Roscilli, Luigi Aurisicchio, Riccardo Bertini, Marcello Allegretti, Maurizio Pesce
Published in:
Nature
Sars-CoV-2

NGF for brain injuries: a groundbreaking trial completed in Italy

10/05/2023
Authors: Antonietta Curatola, Benedetta Graglia, Giuseppe Granata, Giorgio Conti, Lavinia Capossela, Luigi Manni, Serena Ferretti, Daniela Di Giuda, Domenico Marco Romeo, Maria Lucia Calcagni, Marzia Soligo, Enrico Castelli, Marco Piastra, Flavio Mantelli, Giacomo Della Marca, Susanna Staccioli, Tiziana Romeo, Marcello Pani, Fabrizio Cocciolillo, Aldo Mancino, Antonio Gatto, Antonio Chiaretti
Published in:
Biology Direct
Pain & Antiflammation

Marcello Allegretti,

Chief Scientific Officer